Advertisement
FDA limits CBD advertising

FDA limits CBD advertising



A company recently sent the Arkansas Times a press release advertising its cannabidiol (CBD) products, claiming they help with “relief of chronic pain,” “anti-inflammatory benefits,” “anxiety relief,” “sleep,” and “Cancer, Parkinson’s, and Diabetes fighting properties.”

Making such claims is against FDA guidelines. The FDA is researching cannabidiol “as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public.” Therefore, you cannot sell CBD as a dietary supplement — it’s a drug. The FDA recently wrote warnings to a group of CBD sellers about this.


Originally published on ArkTimes.com.

Cannabiz

ArkansasCannabiz is for industry insiders only.
Enter the code you received in your email.

Don't have the code or forgot it?

Access is limited to those in the medical marijuana industry. No end consumers. Please email Lee@arktimes.com to be verified and get an access code.